TerminatedNot Applicable

Detecting Beta-amyloid in the Retina

Stopped: This study has been transferred to the Human Research Ethics Committee of St Vincent's Hospital Melbourne.

Australia186 participantsStarted 2016-02-04

Plain-language summary

Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting "hypercube" of data provides detailed information about retinal structure. Previous research has demonstrated a potential role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. This study aims to further evaluate the use of hyperspectral retinal imaging in the assessment of individuals with dementia or those at risk of Alzheimer's disease.

Who can participate

Age range

30 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged 30 years and older * Diagnosis of Alzheimer's disease or no evidence of Alzheimer's disease (including control participants or those with other neurodegenerative conditions such as Parkinson's disease, Lewy body dementia, or vascular dementia) * Prior confirmation of Alzheimer's disease diagnosis by genetic testing or positron emission tomography (PET) scan (where applicable) * Able to undergo cognitive assessment if required (for control participants without recent testing within the past 6 months) * No major ocular conditions that would preclude retinal imaging * Willing and able to attend the Royal Victorian Eye and Ear Hospital * Able to attend with a friend or family member Exclusion Criteria: * Presence of significant ocular disease that prevents adequate retinal imaging * Inability to undergo study procedures or comply with study requirements * Any condition that, in the opinion of the investigators, would make participation unsafe or compromise data quality

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Diagnostic performance of hyperspectral retinal imaging for detection of Alzheimer's disease-related beta-amyloid

Timeframe: Single study visit (baseline imaging session; approximately 60 minutes)

Trial details

NCT IDNCT07529912

SponsorCenter for Eye Research Australia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-01-09

View on ClinicalTrials.gov More Dementia trials